SLC6A3 and Parkinson disease: Despite progress in neuroimaging and molecular research, PD diagnosis remains primarily clinical, as no definitive biomarker or imaging modality has been established for routine use.10Techniques such as magnetic resonance imaging (MRI), positron-emission tomography (PET), and dopamine transporter (DAT) scans may support diagnosis in selected cases.11, 12, 13However, in public healthcare settings, particularly those with limited resources, access to multidisciplinary care is often constrained, leading to delays in diagnosis and suboptimal disease management.14